

SUMMARY - TRIGGER REDEEMABLE AND PHOENIX SECURITIES

INTRODUCTION AND WARNINGS

Name of the Securities: Trigger Yield Equity-linked Securities due July 2023 linked to Sarepta Therapeutics Inc, BioMarin Pharmaceutical Inc, Vertex Pharmaceuticals Inc and Neurocrine Biosciences Inc (ISIN: XS2365553309; Series Number: SPLB2021-1Y0D) (the "Securities").

The Issuer: The Issuer is Credit Suisse AG ("CS"), acting through its London Branch at One Cabot Square, London, E14 4QJ, United Kingdom and its Legal Entity Identifier (LEI) is: ANGGYXNX0JLX3X63JN86.

Competent authority: The Base Prospectus, under which the Securities are offered, was approved on 9 July 2021. The competent authority approving the Securities Note and the Registration Document (each as supplemented from time to time) comprising the Base Prospectus is the Luxembourg *Commission de Surveillance du Secteur Financier* of 283, route d'Arlon, L-1150 Luxembourg (Telephone number: (+352) 26 25 1-1; Fax number: (+352) 26 25 1-2601; Email: direction@cssf.lu).

This Summary should be read as an introduction to the prospectus (including the Final Terms). Any decision to invest in the Securities should be based on a consideration of the prospectus as a whole. Investors could lose all or part of the invested capital. Where a claim relating to the information contained in the prospectus is brought before a court, the plaintiff investor might, under national law, have to bear the costs of translating the prospectus before the legal proceedings are initiated. Civil liability attaches only to those persons who have tabled the summary, including any translation thereof, but only where the summary is misleading, inaccurate or inconsistent, when read together with the other parts of the prospectus or where it does not provide, when read together with the other parts of the prospectus, key information in order to aid investors when considering whether to invest in the Securities.

You are about to purchase a product that is not simple and may be difficult to understand.

KEY INFORMATION ON THE ISSUER

Who is the Issuer of the Securities?

Domicile and legal form, law under which the Issuer operates and country of incorporation

Credit Suisse AG ("CS" or "Credit Suisse") (ANGGYXNX0JLX3X63JN86) is incorporated under Swiss law as a corporation (*Aktiengesellschaft*) and domiciled in Zurich, Switzerland and operates under Swiss law.

Issuer's principal activities

The principal activities of CS are the provision of financial services in the areas of private banking, investment banking and asset management.

Major shareholders, including whether it is directly or indirectly owned or controlled and by whom

CS is wholly owned by Credit Suisse Group AG.

Key managing directors

The key managing directors of the issuer are members of the issuer's Executive Board. These are: Thomas Gottstein (Chief Executive Officer), Romeo Cerutti, Lydie Hudson, Ulrich Körner, David R. Mathers, Christian Meissner, Joachim Oechslin, Antoinette Poschung, Helman Sitohang, James B. Walker and Philipp Wehle.

Statutory auditors

CS's independent auditor and statutory auditor for the fiscal year ending 31 December 2020 was PricewaterhouseCoopers AG, Birchstrasse 160 CH-8050 Zurich, Switzerland.

CS's independent auditor and statutory auditor for the fiscal years ending 31 December 2019 and 31 December 2018 was KPMG AG, Râffelstrasse 28, 8045 Zurich, Switzerland.

CS has mandated BDO AG, Fabrikstrasse 50, 8031 Zurich, as special auditor for the purposes of issuing the legally required report for capital increases in accordance with Article 652f of the Swiss Code of Obligations.

What is the key financial information regarding the Issuer?

CS derived the key financial information included in the tables below as of and for the years ended 31 December 2020, 2019 and 2018 from the Annual Report 2020, except where noted. The key financial information included in the tables below as of and for the three months ended 31 March 2021 and 31 March 2020 was derived from the Form 6-K Dated 22 April 2021 and the Form 6-K Dated 6 May 2021.

The consolidated financial statements were prepared in accordance with accounting principles generally accepted in the US (US GAAP) and are stated in Swiss francs (CHF).

CS consolidated statements of operations					
(CHF million)	Interim 3 months ended 31 March 2021 (unaudited)	Interim 3 months ended 31 March 2020 (unaudited)	Year ended 31 December 2020 (audited)	Year ended 31 December 2019 (audited)	Year ended 31 December 2018 (audited)
Net revenues	7,653	5,785	22,503	22,686	20,820
Of which: Net interest income	1,643	1,536	5,960	7,049	7,125

Of which: Commissions and fees	3,751	2,920	11,850	11,071	11,742
Of which: Trading revenues	1,800	878	3,178	1,773	456
Provision for credit losses	4,399	568	1,092	324	245
Total operating expenses	4,091	4,124	18,200	17,969	17,719
Of which: Commission expenses	329	345	1,256	1,276	1,259
Income/(loss) before taxes	(837)	1,093	3,211	4,393	2,856
Net income/(loss) attributable to shareholders	(214)	1,213	2,511	3,081	1,729

CS consolidated balance sheets			
(CHF million)	As of 31 March 2021 (unaudited)	As of 31 December 2020 (audited)	As of 31 December 2019 (audited)
Total assets	855,597	809,688	790,459
Of which: Net loans	313,198	300,341	304,025
Of which: Brokerage receivables	47,684	35,943	35,648
Total liabilities	806,242	762,629	743,696
Of which: Customer deposits	407,082	392,039	384,950
Of which: Short-term borrowings	30,556	21,308	28,869
Of which: Long-term debt	164,443	160,279	151,000
Of which: Brokerage payables	26,892	21,655	25,683
Total equity	49,355	47,059	46,763
Of which: Total shareholders' equity	48,593	46,264	46,120
Metrics (in %)			
Swiss CET1 ratio	14.1	14.7	14.4
Swiss TLAC ratio	34.8	35.3	32.6
Swiss TLAC leverage ratio	10.8	12.3	10.4

What are the key risks that are specific to the Issuer?

The Issuer is subject to the following key risks:

- Liquidity risk arising from potential inability to borrow or access the capital markets on suitably favourable terms (including due to adverse changes in its credit ratings) or to sell its assets. This may also arise from increased liquidity costs. CS relies significantly on its deposit base for funding, which may not continue to be a stable source of funding over time.
- Risks arising from the impact of market fluctuations and volatility on CS's investment activities (against which its hedging strategies may not prove effective). The spread of COVID-19 and resulting tight government controls and containment measures implemented around the world have caused severe disruption to global supply chains and economic activity, and the market has entered a period of significantly increased volatility. The spread of COVID-19 is continuing to have an adverse impact on the global economy, the severity and duration of which is difficult to predict, and has adversely affected CS's business, operations and financial performance. In addition, there can be no assurance that, even after adjustments are made to model outputs, the Group will not recognize unexpected losses arising from the uncertainty relating to its modelling for current expected credit losses that has resulted from the COVID-19 pandemic. The COVID-19 pandemic has significantly impacted, and is likely to continue to adversely affect CS's credit loss estimates, mark-to-market losses, trading revenues, net interest income and potential goodwill assessments, and may also adversely affect its ability to successfully realize its strategic objectives. To the extent the COVID-19 pandemic continues to adversely affect the global economy, and/or CS's

business, operations or financial performance, it may also have the effect of increasing the likelihood and/or magnitude of other risks described herein, or may give rise to other risks not presently known to CS or not currently expected to be significant to its business, operations or financial performance. CS is closely monitoring the potential adverse effects and impact on its operations, businesses and financial performance, including liquidity and capital usage, though the extent of the impact is difficult to fully predict at this time due to the continuing evolution of this uncertain situation. CS is also exposed to other unfavourable economic, monetary, political, legal, regulatory and other developments in the countries in which it operates (as well as countries in which CS does not currently conduct business), including uncertainties regarding the expected discontinuation of benchmark rates. CS's significant positions in the real estate sector – and other large and concentrated positions – may also expose it to larger losses. Many of these market risk factors, including the impact of COVID-19, may increase other risks, including CS's credit risk exposures, which exist across a large variety of transactions and counterparties and in respect of which it may have inaccurate or incomplete information. These are exacerbated by adverse economic conditions and market volatility, including as a result of any defaults by large financial institutions (or any concerns relating thereto). The suspension and ongoing liquidation of certain supply chain finance funds and the failure of a US-based hedge fund to meet its margin commitments (and CS's exit from its positions relating thereto) may continue to have negative consequences for CS.

3. CS's ability to implement its current strategy, which is based on a number of key assumptions, is subject to various factors outside its control, including market and economic conditions and changes in law. The implementation of CS's strategy may increase its exposure to certain risks, including credit risks, market risks, operational risks and regulatory risks. The implementation of CS's strategy relating to acquisitions and other similar transactions subjects it to the risk that it may assume unanticipated liabilities (including legal and compliance issues), as well as difficulties relating to the integration of acquired businesses into its existing operations.
4. Country, regional and political risk in the regions in which CS has clients or counterparties, which may affect their ability to perform their obligations to CS. In part because an element of its strategy is to increase CS's private banking businesses in emerging market countries, it may face increased exposure to economic, financial and political disruptions in those countries, which could result in significant losses. Related fluctuations in exchange rates for currencies (particularly for the US dollar) may also adversely affect CS.
5. A wide variety of operational risks arising from inadequate or failed internal processes, people or systems or from external events, including breaches of cyber-security and other failures of information technology. CS relies heavily on financial, accounting and other data processing systems, which are varied and complex, and may face additional technology risks due to the global nature of its operations. CS is thereby exposed to risks arising from human error, negligence, employee misconduct, fraud, malice, accidental technology failure, cyber-attack and information or security breaches. This also exposes CS to risk from non-compliance with existing policies or regulations. Protecting against threats to CS's cyber-security and data protection systems requires significant financial and human resources. The ongoing global COVID-19 pandemic has increased the vulnerability of CS's information technology systems and the likelihood of damage as a result of a cybersecurity incident because of the wide-scale and prolonged shift to remote working for CS's employees and the increased reliance by CS's customers on remote (digital) banking services. CS's existing risk management procedures and policies may not always be effective against such risks, particularly in highly volatile markets, and may not fully mitigate its risk exposure in all markets or against all types of risk. Moreover, CS's actual results may differ materially from its estimates and valuations, which are based upon judgment and available information and rely on predictive models and processes. The same is true of CS's accounting treatment of off-balance sheet entities, including special purpose entities, which requires it to exercise significant management judgment in applying accounting standards; these standards (and their interpretation) have changed and may continue to change. In addition, physical and transition climate risks could have a financial impact on CS either directly, through its physical assets, costs and operations, or indirectly, through its financial relationships with its clients.
6. CS's exposure to legal risks is significant and difficult to predict and the volume and amount of damages claimed in litigation, regulatory proceedings and other adversarial proceedings against financial services firms continues to increase in many of the principal markets in which CS operates. Changes in regulation (including in relation to sanctions) and monetary policy applicable to CS (as well as regulations and changes in enforcement practices applicable to its clients) may adversely affect its business and ability to execute its strategic plans and increase costs, as well as impact the demand from clients for CS's services. Moreover, CS's ability to attract and retain customers, clients, investors and employees, and conduct business transactions with its counterparties, could be adversely affected to the extent its reputation is damaged, which could arise from various sources, including if its procedures and controls fail (or appear to fail). In addition, Swiss resolution proceedings may affect CS's shareholders and creditors.
7. CS faces intense competition in all financial services markets, which has increased as a result of consolidation, as well as emerging technology and new trading technologies (including trends towards direct access to automated and electronic markets and the move to more automated trading platforms). In such a highly competitive environment, CS's performance is affected by its ability to recruit and retain highly skilled employees.

KEY INFORMATION ON THE SECURITIES

What are the main features of the Securities?

Type, class and security identification number(s): The Securities of a Series are notes in bearer form governed by English law and will be uniquely identified by ISIN: XS2365553309; Common Code: 236555330; Swiss Security Number: 59954711; Series Number: SPLB2021-1Y0D.

Currency, nominal amount/denomination, aggregate nominal amount and term of the Securities:

The currency of the Securities will be United States Dollar ("**USD**") (the "**Settlement Currency**"). The nominal amount (the "**Nominal Amount**") or specified denomination (the "**Specified Denomination**") per Security is USD 1,000.00. USD 1,131,000.00 in aggregate nominal amount of Securities will be issued.

The term of the Securities is from the issue date to the Maturity Date. The scheduled maturity date (the "**Maturity Date**") of the Securities is 5 currency business days following the Final Fixing Date (expected to be 28 July 2023).

Rights attached to the Securities: The Securities will give each holder of Securities (a "**Securityholder**") the right to receive the following:

- the Interest Amount(s) payable; and
- the potential payment of a Trigger Barrier Redemption Amount following the occurrence of a Trigger Event; or
- the payment of the Redemption Amount on the Maturity Date.

INTEREST AMOUNT(S)

The Securities shall bear interest at 2.25% of the Nominal Amount per Security. Interest will accrue from, and including, the issue date to, but excluding, 28 July 2023, such interest being payable in arrear on each Interest Payment Date. The Interest Payment Date(s) will be each of: 28 October 2021, 28 January 2022, 28 April 2022, 28 July 2022, 28 October 2022, 30 January 2023, 28 April 2023 and 28 July 2023.

TRIGGER BARRIER REDEMPTION AMOUNT

If a Trigger Event occurs, the Issuer shall redeem the Securities on the Trigger Barrier Redemption Date at the Trigger Barrier Redemption Amount in respect of such Trigger Barrier Redemption Date, together with any Interest Amount payable on such Trigger Barrier Redemption Date. For the avoidance of doubt, upon the occurrence of a Trigger Event, no Redemption Amount and no further Interest Amounts shall be payable after such Trigger Barrier Redemption Date.

Where:

- **Trigger Barrier Redemption Amount:** 100 per cent. of the Nominal Amount.

n	Trigger Barrier Observation Date _n	Trigger Barrier _n	Trigger Barrier Redemption Date _n
1	21 January 2022	97% of the relevant Strike Price	5 currency business days following the occurrence of a Trigger Event
2	21 April 2022	94% of the relevant Strike Price	5 currency business days following the occurrence of a Trigger Event
3	21 July 2022	91% of the relevant Strike Price	5 currency business days following the occurrence of a Trigger Event
4	21 October 2022	88% of the relevant Strike Price	5 currency business days following the occurrence of a Trigger Event
5	21 January 2023	85% of the relevant Strike Price	5 currency business days following the occurrence of a Trigger Event
6	21 April 2023	82% of the relevant Strike Price	5 currency business days following the occurrence of a Trigger Event
7	21 July 2023	79% of the relevant Strike Price	5 currency business days following the occurrence of a Trigger Event

- **Trigger Event:** if on any Trigger Barrier Observation Date, the Level of each underlying asset at the Valuation Time is at or above the Trigger Barrier.

REDEMPTION AMOUNT

The Issuer shall redeem the Securities on the Maturity Date at the redemption amount (the "**Redemption Amount**"), determined in accordance with paragraph (a) or (b) below:

- (a) if a Knock-in Event has occurred, the *product* of (i) the Nominal Amount and (ii) the Worst Final Price *divided* by the Worst Redemption Strike Price, subject to a maximum amount equal to 100 per cent. of the Nominal Amount; or
- (b) if no Knock-in Event has occurred, the *product* of (i) the Nominal Amount and (ii) 100 per cent.

If a Trigger Event occurs, then no Redemption Amount shall be payable and the Securities will be redeemed pursuant to "Trigger Barrier Redemption Amount" above.

Where:

- **Final Fixing Date:** 21 July 2023.
- **Final Price:** the Level of the relevant underlying asset at the Valuation Time on the Final Fixing Date.
- **Initial Setting Date:** 21 July 2021.
- **Knock-in Barrier:** 70% of the relevant Strike Price.
- **Knock-in Event:** if on the Knock-in Observation Date, the Level of any underlying asset at the Valuation Time is below the Knock-in Barrier of such underlying asset.
- **Knock-in Observation Date(s):** 21 July 2023.
- **Level:** the price of the relevant underlying asset quoted on the relevant exchange.
- **Redemption Strike Price:** 70% of the relevant Strike Price.
- **Strike Price:** the Level of the relevant underlying asset at the Valuation Time on the Initial Setting Date.
- **Underlying Asset Return:** the Final Price of the relevant underlying asset *divided* by its Strike Price.
- **Valuation Time:** the scheduled closing time on the relevant exchange.
- **Worst Final Price:** the Final Price of the underlying asset with the lowest Underlying Asset Return.
- **Worst Redemption Strike Price:** the Redemption Strike Price of the underlying asset with the lowest Underlying Asset Return.

Adjustments to valuation and payment dates: Dates on which the underlying asset(s) are scheduled to be valued or on which payments are scheduled to be made may be subject to adjustment for non-underlying asset days, disruptions or non-business days in accordance with the conditions of the Securities.

Underlying asset(s): The underlying assets to which the Securities are linked are a basket of shares (Sarepta Therapeutics Inc (ISIN: US8036071004; Bloomberg code: SRPT UW Equity), BioMarin Pharmaceutical Inc (ISIN: US09061G1013; Bloomberg code: BMRN UW Equity), Vertex Pharmaceuticals Inc (ISIN: US92532F1003; Bloomberg code: VRTX UW Equity) and Neurocrine Biosciences Inc (ISIN: US64125C1099; Bloomberg code: NBIX UW Equity)).

Information on the underlying assets can be found free of charge respectively at: Sarepta Therapeutics Inc: <https://www.nasdaq.com>, BioMarin Pharmaceutical Inc: <http://www.nasdaq.com>, Vertex Pharmaceuticals Inc: <http://www.nasdaq.com> and Neurocrine Biosciences Inc: <https://www.nasdaq.com/>.

<p>Status of the Securities: The Securities are unsubordinated and unsecured obligations of the Issuer and will rank equally among themselves and with all other unsubordinated and unsecured obligations of the Issuer from time to time outstanding.</p>
<p>Description of restrictions on free transferability of the Securities: The Securities are freely transferable (subject to all applicable laws).</p>
<p>Where will the Securities be traded?</p>
<p>Application will be made to admit the Securities to trading on the regulated market of the Luxembourg Stock Exchange on or around the issue date.</p>
<p>What are the key risks that are specific to the Securities?</p>
<ol style="list-style-type: none"> 1. Risks in case of an insolvency or resolution measures in respect of the Issuer. An investment in the Securities constitutes unsecured obligations of the Issuer and will not be covered by any statutory or other deposit protection scheme and does not have the benefit of any guarantee. Therefore in the event of the insolvency of the Issuer, an investor in the Securities may lose all or some of its investment therein irrespective of any favourable development of the other value determining factors, such as the performance of the underlying asset(s). Similarly, prior to an insolvency of the Issuer, rights of the holders of the Securities may be adversely affected by the Swiss Financial Market Supervisory Authority FINMA's broad statutory powers in the case of a restructuring proceeding in relation to Credit Suisse, including its power to convert the Securities into equity and/or partially or fully write-down the Securities. 2. Potential loss of some or all of the investment. The Securities are "capital at risk" investments and investors may lose some or all of their money depending on the performance of the relevant underlying asset(s). Securityholders will be exposed to the performance of the underlying asset which has the worst performance of a basket of underlying assets, irrespective of how the other underlying assets perform. Therefore, if such underlying asset fails to meet the specified threshold or barrier and a Knock In Event occurs or if the amount payable on redemption of the Securities is less than the purchase price paid by investors for the Securities, investors may lose some or all of their investment. In addition, if the Securities are sold in the secondary market for less than the purchase price paid by the relevant investor, investors could lose some or all of their investment. 3. Risks in connection with redemption of the Securities at the unscheduled termination amount. The Securities may be redeemed at the unscheduled termination amount in certain circumstances, including: following the occurrence of an event of default or for illegality reasons or following certain events affecting the Issuer's hedging arrangements or the underlying asset(s). In such circumstances, the unscheduled termination amount is likely to be less than the original purchase price and could be as low as zero and, following any such early redemption, investors may be unable to reinvest the proceeds in an investment having a comparable return. Following the occurrence of any such event, no other amounts on account of interest or otherwise shall be payable by the Issuer in respect of the Securities. 4. Risks in connection with discretionary rights of the Calculation Agent and related termination rights of the Issuer. Upon the occurrence of an adjustment event or an extraordinary event, the Issuer or Calculation Agent has broad discretion to make certain modifications to the terms and conditions of the Securities to account for such event, without the consent of the Securityholders, including but not limited to, adjusting the calculation of the value of any underlying assets or any amount payable or other benefit to be received under the Securities, substituting any underlying asset. Any such adjustment, postponement, alternative valuation or substitution could have a material adverse effect on the return on, and value of, the Securities and shall be made without the consent of the Securityholders. 5. Early redemption following a Trigger Event. As the Securities have a trigger feature, the timing of redemption of the Securities is uncertain as the occurrence of a Trigger Event will be dependent on the performance of the underlying asset(s). In the case of an unfavourable development of the value of the underlying asset(s), any redemption may only occur on the scheduled maturity date and the amount payable on redemption of the Securities will be determined based on the unfavourable performance of the underlying asset(s). In such circumstances, the return on the Securities may be less than the amount originally invested and less than an investor would have received had a Trigger Event occurred. 6. Securities with barrier features. As the terms of the Securities have a barrier feature, amounts payable under the Securities will depend on the value or performance of the underlying asset(s) satisfying the relevant condition. If such condition is not satisfied, payments in respect of the Securities may be determined by reference to the performance of the underlying asset(s) which may affect the value of and return on the Securities. 7. Risks associated with shares. The performance of a share is dependent upon macroeconomic factors which may adversely affect such performance and, in turn, the value of the Securities. The issuer of a share has no obligation to any Securityholder and may take any actions in respect of such share without regard to the interests of Securityholders which could adversely affect the market value of and return on the Securities. Securityholders will not participate in dividends or other distributions paid on such share. 8. Risks in connection with the secondary market. The secondary market for the Securities may be limited, may never develop at all or may not continue even though the Securities are listed, which may adversely impact the market value of such Securities or the ability of the investor thereof to sell such Securities. In addition, the market value of the Securities will be affected by factors beyond the control of the Issuer, such as the creditworthiness of the Issuer, the remaining time to maturity of the Securities, interest and yield rates, the value and volatility of the underlying asset(s), anticipated dividends, the occurrence of certain events in relation to the underlying asset(s), and national and international events.
<p>KEY INFORMATION ON THE OFFER OF THE SECURITIES TO THE PUBLIC AND THE ADMISSION TO TRADING ON A REGULATED MARKET</p>
<p>Under which conditions and timetable can I invest in this Security?</p>
<p>Issue/offer of the Securities: The Securities have been offered to the dealer at the issue price of 100.00% of the aggregate nominal amount. The Securities are not being publicly offered.</p>
<p>Issue date and admission to trading: The issue date of the Securities is 28 July 2021 and application will be made for the Securities to be listed and admitted to trading on or around the issue date.</p>
<p>Estimated total expenses of the issue/offer, including estimated expenses charged to the purchaser by the Issuer/offeror:</p>
<p>There are no estimated expenses charged to the purchaser by the Issuer and distributor(s).</p> <p>The Securities will be sold by the Dealer to the distributor(s) at a discount of up to 6 per cent. of the Issue Price. Such discount represents the fee retained by the distributor(s) out of the Issue Price paid by investors</p>
<p>Who is the offeror and/or the person asking for admission to trading?</p>

The Issuer is the entity requesting for the admission to trading of the Securities.

Why is this prospectus being produced?

Reasons for the issue/offer, estimated net proceeds and use of proceeds: The net proceeds from the issue of the Securities, which are expected to amount to USD 1,131,000.00, will be used by the Issuer for its general corporate purposes (including hedging arrangements).

Underwriting agreement on a firm commitment basis: The offer of the Securities is not subject to an underwriting agreement on a firm commitment basis.

Material conflicts pertaining to the issue/offer: Fees are payable to the distributor(s). In making calculations and determinations with regard to the Securities, there may be a difference of interest between the Securityholders and the Issuer, the dealer and their affiliated entities. In particular, the Issuer, the dealers and their affiliated entities may have interests in other capacities (such as other business relationships and activities) and when acting in such other capacities may pursue actions and take steps that they deem necessary to protect their interests without regard to the consequences for any particular Securityholder, which may have a negative impact on the value of and return on the Securities. In the ordinary course of its business the Issuer, the dealers and/or any of their affiliates may effect transactions in relation to underlying asset(s) and may enter into one or more hedging transactions with respect to the Securities. Such activities may affect the market price, liquidity, value of or return on the Securities and could be adverse to the interest of the relevant Securityholders.